113 related articles for article (PubMed ID: 7505869)
21. [Early diagnosis of prostate carcinoma with reference to the density of prostate-specific antigen].
Schmid HP; Ravery V; Toublanc M; Boccon-Gibod L
Schweiz Med Wochenschr; 1996 Sep; 126(36):1530-5. PubMed ID: 8927956
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonography: their roles in diagnosing early prostate cancer.
Cupp MR; Oesterling JE
Mayo Clin Proc; 1993 Mar; 68(3):297-306. PubMed ID: 7682639
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography.
Tsui KH; Chang PL; Wang TM; Hsieh ML
Changgeng Yi Xue Za Zhi; 1997 Mar; 20(1):23-8. PubMed ID: 9178589
[TBL] [Abstract][Full Text] [Related]
24. Intraindividual variations of total and percent free serum prostatic-specific antigen levels in patients with normal digital rectal examination.
Morote J; Raventós CX; Lorente JA; Enbabo G; López M; de Torres I
Eur Urol; 1999 Aug; 36(2):111-5. PubMed ID: 10420031
[TBL] [Abstract][Full Text] [Related]
25. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
26. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
[TBL] [Abstract][Full Text] [Related]
28. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
[TBL] [Abstract][Full Text] [Related]
29. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group.
Stoner E; Round E; Ferguson D; Gormley GJ
J Urol; 1994 May; 151(5):1296-300. PubMed ID: 7512661
[TBL] [Abstract][Full Text] [Related]
30. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
32. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
Hammerer P; Huland H
Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
[TBL] [Abstract][Full Text] [Related]
33. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
Saito Y
Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
[TBL] [Abstract][Full Text] [Related]
34. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
[TBL] [Abstract][Full Text] [Related]
35. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
Karazanashvili GG; Managadze LG
Urologiia; 2000; (6):37-41. PubMed ID: 11186321
[TBL] [Abstract][Full Text] [Related]
36. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
Catalona WJ; Smith DS; Ratliff TL; Dodds KM; Coplen DE; Yuan JJ; Petros JA; Andriole GL
N Engl J Med; 1991 Apr; 324(17):1156-61. PubMed ID: 1707140
[TBL] [Abstract][Full Text] [Related]
37. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
39. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
Iqbal N; Chaughtai N
J Pak Med Assoc; 2005 Aug; 55(8):318-20. PubMed ID: 16164156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
